Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

NCT03520660 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

NCT01995266 ·Status: COMPLETED ·Phase: PHASE3

Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults

NCT03181074 ·Status: COMPLETED

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

NCT04952207 ·Status: UNKNOWN

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

NCT02531269 ·Status: COMPLETED

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C

NCT01464008 ·Status: COMPLETED

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

NCT00663208 ·Status: COMPLETED ·Phase: PHASE2

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

NCT03887637 ·Status: UNKNOWN

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

NCT02753699 ·Status: COMPLETED ·Phase: PHASE3

Glecaprevir/Pibrentasvir Real-world Study in China

NCT03941821 ·Status: UNKNOWN

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

NCT00803309 ·Status: TERMINATED ·Phase: PHASE4

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

NCT02170727 ·Status: COMPLETED ·Phase: PHASE3

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

NCT01628692 ·Status: COMPLETED ·Phase: PHASE2

Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)

NCT02578693 ·Status: COMPLETED

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

NCT02032901 ·Status: COMPLETED ·Phase: PHASE3

Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China(STAT)

NCT05906459 ·Status: UNKNOWN

Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy

NCT05929963 ·Status: UNKNOWN

Qualification of Point-of-Care Assays for Management of HCV Patients

NCT02335320 ·Status: UNKNOWN

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

NCT01390844 ·Status: COMPLETED ·Phase: PHASE3

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

NCT01280656 ·Status: COMPLETED

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

NCT01492504 ·Status: COMPLETED

Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan

NCT00543244 ·Status: UNKNOWN

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

NCT03020004 ·Status: COMPLETED ·Phase: PHASE2